Effect of Pentoxifylline on Organ Dysfunction and Mortality in Severe Sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR201912769388623

Enrollment

100

Registered

2019-12-10

Start date

2017-09-02

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System sepsis

Interventions

pentoxiflylline

placebo

Pentoxifylline infusion maximum dose 1800 mg per day maximum

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1- Adult patients with age =18 years. 2- Patients with severe sepsis. The diagnosis of sever sepsis was established according to the definitions of the Surviving Sepsis Campaign (SSC) (3). 3- Sepsis was due to either nosocomial pneumonia or pelvi-abdominal sepsis

Exclusion criteria

Exclusion criteria: 1. Late septic shock at presentation with multiple organ failure. 2. APACHE II score on admission >25. 3. Preexisting liver cirrhosis. 4. Preexisting end stage renal disease 5. Pregnancy. 6. History of allergy or intolerance to Pentoxifylline. 7. Patient with malignancies 8. Uncontrolled hemorrhage 9. Burn 10. Previous steroid therapy 11. Death within 24 hours of ICU admission

Design outcomes

Primary

Measure	Time frame
oLength of hospital stay. oNeed for and duration of mechanical ventilation. oNeed for and duration of vassopresor and inotropic support. oNeed for haemodialysis	—

Secondary

Measure	Time frame
Length of hospital stay , need for vasopressor or inotrops, need of mechanical ventilation, inflammatory markers CRP and procalcitonin, 28 days survival	—

Countries

Egypt

Contacts

Public Contactamr sobhy

lecturer at department of anesthesia ICU and pain management faculty of medicine ain shams university

dr.amrsobhy2013@gmail.com00201063394383

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026